February 8, 2024, Synlogic Therapeutics announced it would cease operations.
Synlogic Therapeutics is in the process of developing a Synthetic Biotic™ medicine for patients with CBS Deficiency Homocystinuria. To learn more about what this means, click here
March 20, 2023
- Presentations included full data from both the Phase 2 Synpheny-1 Study in PKU and Phase 1 Study for SYNB1353 as a potential treatment for HCU
January 05, 2023
Synlogic Provides Corporate Update and Outlook for 2023
- Pivotal Phase 3 for SYNB1934 in phenylketonuria (PKU) to initiate in H1 2023
- Rare Pediatric Disease Designation received for SYNB1353 for homocystinuria (HCU)
- Cash runway expected into H2 2024
November 30, 2022
Synlogic SYNB1353 Phase 1 Top-line Results (Investor Presentation)
November 30, 2022
- Top-line Phase 1 data in healthy volunteers show that SYNB1353 reduces plasma methionine by consuming methionine in the GI tract
- SYNB1353 has been granted Orphan Drug Designation (ODD) from the FDA for the treatment of homocystinuria (HCU)
- The company confirms expectations for proof-of-concept data for SYNB8802 in enteric hyperoxaluria before year-end and Phase 3 initiation of SYNB1934 for PKU in H1 2023
July 12, 2022
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Classical HCU
- Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)
- Company expects data from the SYNB1353 healthy volunteer study in H2 2022
- Trial marks Synlogic’s third clinical-stage program; data readouts for all programs expected in H2 2022
